Rize Oncology Inc., a biopharmaceutical company, focuses on the development of precision gene editing for human therapeutics applications. It develops STS-201, a small-molecule drug for the treatment of soft tissue sarcoma. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025. Rize Oncology Inc. was incorporated in 2018 and is based in Kelowna, Canada.